IDP-123 Vehicle Lotion

DRUG2 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Acne Vulgaris

Phase 3

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

CompletedNCT03168334

Bausch Health Americas, Inc.Acne Vulgaris

Start: 2017-07-11End: 2018-07-24Updated: 2021-04-01

A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)

CompletedNCT03168321

Bausch Health Americas, Inc.Acne Vulgaris

Start: 2017-06-29End: 2018-06-07Updated: 2021-04-01

Related Papers

Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin.

2023-12-012 citations

Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne

SKIN The Journal of Cutaneous Medicine2023-07-171 citations

Efficacy and Safety of Tazarotene 0.045% Lotion in Caucasian Adults With Moderate-to-Severe Acne.

2022-10-01

Efficacy and tolerability of three topical acne treatments by body mass index: post hoc analysis including overweight and obese patients.

2022-07-14

Dermal sensitization, safety, tolerability, and patient preference of tazarotene 0.045% lotion from five clinical trials.

2021-08-302 citations

Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.

2021-06-012 citations

Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne.

2020-11-013 citations

Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex

Journal of Drugs in Dermatology2020-07-016 citations

Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity

Journal of Drugs in Dermatology2020-06-0110 citations